Back to top
more

Zoetis (ZTS)

(Real Time Quote from BATS)

$178.29 USD

178.29
835,610

-0.54 (-0.30%)

Updated Jun 11, 2024 03:13 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (80 out of 250)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Zoetis Inc. came into existence following Pfizer’s decision to spin off its animal health business. he company is a leader in the discovery, development, manufacture and commercialization of animal health medicines, vaccines and diagnostic products with a focus on both livestock and companion animals. Zoetis has a diversified business, which caters to eight core species — cattle, swine, poultry, fish and sheep (collectively, livestock) and dogs, cats and horses (collectively, companion animals).

Zoetis' (ZTS) Q1 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Zoetis' (ZTS) earnings and revenues trump estimates in the first quarter of 2022.

Zoetis (ZTS) Tops Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Zoetis (ZTS) delivered earnings and revenue surprises of 8.20% and 0.88%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Drug/Biotech Stocks Q1 Earnings Due on May 5: VRTX, ZTS & More

by Zacks Equity Research

Let's look at the five biotech/drug companies, slated to release quarterly results on May 5.

Is a Beat in Store for Zoetis (ZTS) This Earnings Season?

by Zacks Equity Research

Zoetis (ZTS) is set to report earnings and revenue figures and provide updates on its pipeline when it releases first-quarter 2022 results.

Zoetis (ZTS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

by Zacks Equity Research

Zoetis (ZTS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Tenet Healthcare (THC) Q1 Earnings Beat Mark, Surge Y/Y

by Zacks Equity Research

Tenet Healthcare (THC) Q1 earnings gain from a healthy revenue stream, reduced expenses and operational efficiency.

Why the Earnings Surprise Streak Could Continue for Zoetis (ZTS)

by Zacks Equity Research

Zoetis (ZTS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

The Zacks Analyst Blog Highlights PayPal Holdings, Zoetis, CSX, Northrop Grumman, and The Kraft Heinz

by Zacks Equity Research

PayPal Holdings, Zoetis, CSX, Northrop Grumman, and The Kraft Heinz are part of top Analyst Blog.

Sheraz Mian headshot

Top Analyst Reports for PayPal, Zoetis & CSX

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including PayPal Holdings, Inc. (PYPL), Zoetis Inc. (ZTS), and CSX Corporation (CSX).

COLL or ZTS: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

COLL vs. ZTS: Which Stock Is the Better Value Option?

COLL or ZTS: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

COLL vs. ZTS: Which Stock Is the Better Value Option?

Why Is Zoetis (ZTS) Down 1.6% Since Last Earnings Report?

by Zacks Equity Research

Zoetis (ZTS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

COLL or ZTS: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

COLL vs. ZTS: Which Stock Is the Better Value Option?

Neena Mishra headshot

Russia-Ukraine Tensions Escalate: 3 ETFs to Buy

by Neena Mishra

Russian aggression against Ukraine has sent commodities and gold higher

Company News for Feb 16, 2022

by Zacks Equity Research

Companies In The News Are: MAR, ZTS, TRP, ANET.

Zoetis' (ZTS) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Zoetis' (ZTS) earnings and revenues beat estimates for the fourth quarter of 2021.

Zoetis (ZTS) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Zoetis (ZTS) is set to report earnings and revenue figures and provide updates on its pipeline when it releases fourth-quarter 2021 results.

Mark Vickery headshot

Top Stock Reports for Microsoft, Amazon & Tesla

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corporation (MSFT), Amazon.com, Inc. (AMZN), and Tesla, Inc. (TSLA).

Zoetis (ZTS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Zoetis (ZTS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Mednax (MD) Buys Night Lite Pediatrics to Boost Portfolio

by Zacks Equity Research

Mednax (MD) purchases Night Lite Pediatrics, LLC in Orlando to enhance its pediatric business line.

Sanofi's (SNY) Enjaymo Gets FDA Nod For Rare Blood Disorder

by Zacks Equity Research

The FDA approves Sanofi's (SNY) Enjaymo for the treatment of hemolysis in adult patients with cold agglutinin disease. Enjaymo is the first therapy to be approved for this indication.

The Zacks Analyst Blog Highlights: General Motors Co., Tesla Inc., Marvell Technology Inc., FedEx Corp. and Zoetis Inc

by Zacks Equity Research

General Motors Co., Tesla Inc., Marvell Technology Inc., FedEx Corp. and Zoetis Inc are highlighted in this Analyst Blog article.

Nalak Das headshot

Top 5 Stocks to Buy on the Dip Despite Market Fluctuations

by Nalak Das

We have narrowed our search to five U.S. corporate giants (market capital > $50 billion) that are currently trading on the dip. These are: TSLA, GM, FDX, MRVL and ZTS.

Here's Why Seasoned Investors are Retaining Mednax (MD)

by Zacks Equity Research

Banking on its strategic measures and a streamlined business, Mednax (MD) holds potential to reap benefits for investors.

Why Holding Anthem (ANTM) in Your Portfolio is a Prudent Move?

by Zacks Equity Research

Riding high on its strategic measures and a rising membership, Anthem (ANTM) holds prospects to reap benefits for investors.